Sanofi's (SANL) 3QCY17 revenue increased ~7% YoY (+11% QoQ) to INR6.7b (~3.4% miss). EBITDA rose 27% YoY to INR1.8b (+21% beat), as margins expanded ~440bp YoY (+830bp QoQ) to 27.5%. Consequently, PAT increased sharply by 44% YoY to INR1.2b (31% beat). High-single-digit revenue growth, coupled with strong margin: According to AIOCD, secondary sales growth for SANL stood at ~6% YoY, higher than industry, which saw flattish growth of 1%. The company's key therapeutic areas posted strong growth during the quarter: Anti-Diabetic portfolio grew...